FAP+ cells can both promote tumor progression directly and present a barrier to immunotherapies through their production of ECM and direct signaling pathways (Puré and Blomberg, 2018; Lo et al., 2017; Lee et al., 2011). The gene discussed is FAP; the disease is neoplasm.